Dr. Syed I. Mobin, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,415
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license ME79439 -
Critical Care Medicine (Internal Medicine) Physician
FL license ME79439 -
Sleep Medicine (Internal Medicine) Physician
FL license ME79439
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Orlando Orlando, FL
Medical groups
- Florida Hospital Medical Group Inc (1,755 clinicians)
- Central Florida Pulmonary Group PA (15 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,415
- Services billed
- 3,926
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 1,174 | 564 |
| Established patient office or other outpatient visit, 30-39 minutes | 513 | 273 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 476 | 288 |
| Test to measure expiratory airflow and volume | 205 | 187 |
| Test to determine lung volumes using sensors | 190 | 173 |
| Test to examine how well the lungs exchange gases | 184 | 169 |
| X-ray of chest, 2 views | 181 | 152 |
| Established patient office or other outpatient visit, 20-29 minutes | 157 | 108 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 130 | 124 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 115 | 111 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Orlando, FL | 313 |
| Montelukast Sodium Other prescribers in Orlando, FL | 212 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Orlando, FL | 200 |
| Ambrisentan | 88 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Orlando, FL | 80 |
| Prednisone Other prescribers in Orlando, FL | 74 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Orlando, FL | 59 |
| Adempas (riociguat) | 47 |
| Doxycycline Hyclate Other prescribers in Orlando, FL | 45 |
| Fluticasone Propionate Other prescribers in Orlando, FL | 44 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 38 payments worth $1,119 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $185 |
|---|---|
| Insmed, Inc. | $178 |
| Inspire Medical Systems, Inc. | $147 |
| GlaxoSmithKline, LLC. | $107 |
| Actelion Pharmaceuticals US, Inc. | $79.99 |
| Merck Sharp & Dohme LLC | $77.10 |
| Harmony Biosciences LLC | $73.20 |
| Genzyme Corporation | $56.01 |
| Food and Beverage | $893 |
|---|---|
| Education | $226 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. May 27, 2025 | Education OPSUMIT; UPTRAVI · Cardiology · in-kind | $79.99 |
| Amgen Inc. Jul 31, 2025 | Education in-kind | $34.00 |
| Merck Sharp & Dohme LLC Nov 11, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Aug 8, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Nov 11, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Insmed, Inc. Nov 7, 2025 | Education Brinsupri; Brinsupri · Respiratory · in-kind | $17.38 |
| Insmed, Inc. Aug 13, 2025 | Education in-kind | $17.38 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $97,248 in research payments for these studies, mostly to the institutions running them.
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics Corporation · Enrolling by invitation · NCT04905693 - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782 - A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
Amgen Inc. - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc. - A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate th…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.